Ondine Biomedical (LON:OBI) Trading Down 2.3% - Time to Sell?

Key Points

• Price/volume move: Shares fell about 2.3% to C$10.50 intraday (low C$10.10) on extremely light trading — ~1,064 shares vs an average daily volume of ~340,807.
• Financial/technical snapshot: Market cap is C$5.46 billion with a negative P/E (-1.50), high debt-to-equity (76.45) but a strong quick ratio (8.26); the stock sits near its 200‑day moving average (C$10.94) while the 50‑day is C$9.90.
• Business focus: Ondine develops patented photodisinfection therapies to prevent and treat infections, including antimicrobial‑resistant pathogens, with the technology used in over 100,000 patient treatments.

Ondine Biomedical Inc. (LON:OBI - )'s stock price was down 2.3% during mid-day trading on Thursday . The stock traded as low as C$10.10 and last traded at C$10.50. Approximately 1,064 shares were traded during trading, a decline of 100% from the average daily volume of 340,807 shares. The stock had previously closed at C$10.75.

Ondine Biomedical Trading Down 2.3%

The stock has a market cap of C$5.46 billion, a price-to-earnings ratio of -1.50 and a beta of 0.32. The company has a quick ratio of 8.26, a current ratio of 0.97 and a debt-to-equity ratio of 76.45. The business has a 50-day moving average of C$9.90 and a 200-day moving average of C$10.94.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target. Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.